NCT00955617

DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases

Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Guerbet · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.

Conditions

• Peripheral Arterial Disease

Interventions

Type	Name	Description
OTHER	Contrast-enhanced MRA - Imaging examination	Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)

Timeline

• Start date: 2009-07-01
• Primary completion: 2010-06-01
• Completion: 2010-10-01
• First posted: 2009-08-10
• Last updated: 2012-11-02
• Results posted: 2012-11-02

Locations

1 site across 1 country: France